open access

Vol 83, No 2 (2015)
REVIEWS
Submitted: 2015-03-10
Accepted: 2015-03-10
Get Citation

Cardiovascular safety of two bronchodilators’ fixed-dose combination: indacaterol and glycopyrronium

Jerzy Kozielski
DOI: 10.5603/PiAP.2015.0026
·
Pneumonol Alergol Pol 2015;83(2):164-170.

open access

Vol 83, No 2 (2015)
REVIEWS
Submitted: 2015-03-10
Accepted: 2015-03-10

Abstract

Combination therapy with anticholinergics and b2-agonists should be used in COPD patients after failure of previous monotherapy with one of these drugs. Synergistic effect of both mechanisms of bronchodilation can maximize the efficacy of separately administered drugs. The effectiveness of the combination of LABA and LAMA is already confirmed, nevertheless the question about the safety profile of this therapy is still remaining, particularly with regard to the cardiovascular system. The paper discusses the overall safety profile of the combined preparation compare to placebo as well as the active comparators, especially the cardiovascular safety of fixed-dose formulation. Based on the data it has been demonstrated, that the combination of two ultra -long-acting bronchodilators with different complementary mechanisms of action increases the effectiveness of COPD therapy without affecting the safety.

Abstract

Combination therapy with anticholinergics and b2-agonists should be used in COPD patients after failure of previous monotherapy with one of these drugs. Synergistic effect of both mechanisms of bronchodilation can maximize the efficacy of separately administered drugs. The effectiveness of the combination of LABA and LAMA is already confirmed, nevertheless the question about the safety profile of this therapy is still remaining, particularly with regard to the cardiovascular system. The paper discusses the overall safety profile of the combined preparation compare to placebo as well as the active comparators, especially the cardiovascular safety of fixed-dose formulation. Based on the data it has been demonstrated, that the combination of two ultra -long-acting bronchodilators with different complementary mechanisms of action increases the effectiveness of COPD therapy without affecting the safety.

Get Citation

Keywords

combination therapy, indacaterol, glycopyrronium, cardiovascular safety

About this article
Title

Cardiovascular safety of two bronchodilators’ fixed-dose combination: indacaterol and glycopyrronium

Journal

Advances in Respiratory Medicine

Issue

Vol 83, No 2 (2015)

Pages

164-170

DOI

10.5603/PiAP.2015.0026

Bibliographic record

Pneumonol Alergol Pol 2015;83(2):164-170.

Keywords

combination therapy
indacaterol
glycopyrronium
cardiovascular safety

Authors

Jerzy Kozielski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl